The backstory: GLP-1s, a class of drugs that include semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro and Zepbound), were initially prescribed to treat Type 2 diabetes, but have soared in popularity because of weight loss
Fasting plasma glucose improvements occur with both medications, driven by reduced hepatic glucose production
Omega-3, omega-6, and other essential fatty acids influence inflammation, cardiovascular health, cognition, and healthy aging
[3] Weight loss itself, particularly in women with polycystic ovary syndrome (PCOS) and obesity, can restore ovulation before the patient expects it
The success of weight loss achieved with Semaglutide GLP-1 , or any other weight loss program, is not guaranteed to be permanent without continued efforts to maintain a healthy lifestyle
A plausible explanation for the apparent advantage of GLP-1 RAs may involve their superior weight-loss efficacy relative to other antidiabetic drugs, particularly SGLT-2is, which themselves confer substantial CV benefits